Navidea Biopharmaceuticals (NAVB) Announces Positive Initial Results In Single-Center Cohort From Phase 2b Trial Of NAV4694 In Subjects With Mild Cognitive Impairment (MCI)
2/6/2014 10:35:18 AM
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company’s investigational beta-amyloid imaging agent, NAV4694, produced highly differentiated images in the first cohort of subjects enrolled in the Company’s Phase 2b positron emission tomography (PET) imaging study of subjects with Mild Cognitive Impairment (MCI). The subjects were enrolled and evaluated at the Alzheimer's Disease Center at Quincy Medical Center, Quincy, MA. The results indicate that NAV4694 produced high-quality diagnostic images that segregated MCI subjects into two discrete groups, either amyloid-positive or amyloid-negative.
Help employers find you! Check out all the jobs and post your resume.
comments powered by